Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms.

Myeloproliferative neoplasms are characterized by chronic inflammation. The discovery of constitutively active JAK-STAT signaling associated with driver mutations has led to clinical and translational breakthroughs. Insights into the other pathways and novel factors of potential importance are being actively investigated. Various classes of agents with immunomodulating or immunosuppressive properties have been used with varying degrees of success in treating myeloproliferative neoplasms. Early clinical trials are investigating the feasibility, effectiveness, and safety of immune checkpoint inhibitors, cell-based immunotherapies, and SMAC mimetics. The dynamic landscape of immunotherapy and immunomodulation in myeloproliferative neoplasms is the topic of the present review.

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interest N. Pemmaraju: Consulting/honorarium: Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB, Pacylex. Research funding/clinical trials support: Stemline; Novartis; Abbvie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix, SagerStrong Foundation N.C. Chen: None S. Verstovsek: Consulting: Constellation; Pragmatist; Sierra; Incyte; Novartis; Celgene; Research funding/clinical trials support: Incyte Corporation; Roche; NS Pharma; Celgene; Gilead; Promedior; CTI BioPharma Corp.; Genentech; Blueprint Medicines Corp.; Novartis; Sierra Oncology; Pharma Essentia; Astrazeneca; Ital Pharma; Protagonist Therapeutics.